Sparks commentary

TMT

Sparks

Brave Bison (LSE: BBSN) points to full-year upgrades
Published by Fiona Orford-Williams

Brave Bison’s first-half results show the effect on revenue of pulling away from less profitable North American business and the consequent improvement in adjusted EBITDA margins. With increased operational leverage on a lower fixed cost base, the group now expects to outstrip broker expectations for the full year, helped further by good new client wins. With a cash-positive balance sheet and a cashflow weighting to the second half, Brave Bison still has ambitions on the M&A front, having walked away from its earlier approach to Mission Group, and has the funding to continue developing its own AI-driven tools to enhance its offering.

Latest

Healthcare | Comment

Herantis Pharma (HEL: HRTIS) – a step closer to Phase II

Investment Companies | Comment

The Biotech Growth Trust (BIOG) reported encouraging H126 results

TMT | Comment

Nanoco (LSE:NANO) settles LG litigation for $5m

Healthcare | Comment

Mendus (OMX: IMMU) announces c SEK50m directed share issue